Mavacamten meets primary and secondary endpoints in phase III EXPLORER-HCM clinical trial of patients with symptomatic, obstructive hypertrophic cardiomyopathy

Following positive results (meaningful improvements in symptoms, functional status, quality of life, reduction/elimination in obstruction of left ventricle), the filing of a New Drug Application with FDA for this allosteric modulator of cardiac myosin is planned for early 2021.


Biospace Inc.